High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- VA Office of Research and Development
- Study ID
- NCT05011383
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Metastatic Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- High dose testosterone — DRUGHigh dose testosterone is administered subcutaneously once monthly until progression or toxicity
Study Details
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Key Dates
- Start date
- Aug 31, 2021
- Status verified
- Jul 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 51 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ATMPatients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
- Experimental: CDK12Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
- Experimental: CHEK2Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
Primary Outcome Measure
PSA response [ Time Frame: 12 weeks ]
Central Contacts
- Robert B Montgomery, MD(206) 277-6878
- Elahe Mostaghel, MD(206) 762-1010
Locations (17)
Find similar trials in Aurora, CO
By research site
Rocky Mountain Regional VA Medical Center, Aurora, CO· Aurora, COVA Connecticut Healthcare System West Haven Campus, West Haven, CT· West Haven, CTNorth Florida/South Georgia Veterans Health System, Gainesville, FL· Gainesville, FLOrlando VA Medical Center, Orlando, FL· Orlando, FLAtlanta VA Medical and Rehab Center, Decatur, GA· Decatur, GARobley Rex VA Medical Center, Louisville, KY· Louisville, KY
Related Studies
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPHASE2/PHASE3 · Recruiting · VA Office of Research and Development · Long Beach, California
- Study of ORIC-944 in Patients With Metastatic Prostate CancerPHASE1 · Recruiting · ORIC Pharmaceuticals · Colorado Springs, Colorado
- Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerPHASE2 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerPHASE1 · Recruiting · Genentech, Inc. · Scottsdale, Arizona